Verastem (NASDAQ:VSTM – Get Rating)‘s stock had its “outperform” rating reiterated by stock analysts at Royal Bank of Canada in a report released on Wednesday, Benzinga reports. They currently have a $3.00 price target on the biopharmaceutical company’s stock.
Several other equities research analysts also recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $3.00 price objective on shares of Verastem in a research note on Wednesday. StockNews.com started coverage on shares of Verastem in a research report on Friday, March 10th. They set a “hold” rating for the company. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $4.25.
Verastem Price Performance
NASDAQ VSTM opened at $0.45 on Wednesday. The firm’s fifty day simple moving average is $0.56 and its two-hundred day simple moving average is $0.58. The company has a current ratio of 4.97, a quick ratio of 4.97 and a debt-to-equity ratio of 0.39. Verastem has a 12-month low of $0.29 and a 12-month high of $2.13. The firm has a market capitalization of $94.96 million, a P/E ratio of -1.10 and a beta of 0.81.
Institutional Inflows and Outflows
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
- Get a free copy of the StockNews.com research report on Verastem (VSTM)
- Don’t Miss Out: $2 Trillion Could be Headed to the Banking Sector
- A Weakening Economy Suggests Caution Before Buying Five Below
- Williams-Sonoma: Time To Buy At Rock-Bottom Prices
- Why DraftKings Could Keep Outperforming in 2023
- Charles Schwab And The Safest 30% You Can Make This Year
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.